Armata Clears Key FDA Milestone, Prepares AP-SA02 Phase 3 Trial for 2026

Armata Pharmaceuticals reaches key regulatory milestone with FDA submission for AP-SA02 Phase 3 trial. Lead bacteriophage candidate targets serious S. aureus infections with new DoD funding.